IBRX 8-K 2026-11-09

ImmunityBio, Inc. (IBRX) 8-K dated 2026-11-09 — accession 0001326110-26-000091.

ImmunityBio, Inc. (IBRX) is a biotechnology company listed on US.

ImmunityBio, Inc. filed a 8-K on 2026-11-09. Accession 0001326110-26-000091.

This 8-K covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.

Not investment advice. The IBRX SEC hub lists recent forms. The stock page is the research view.